MedTrace Logo

Cardiopulmonary Exercise Tests in Patients With Long COVID

NCT06394921 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 146

Last updated 2024-08-22

No results posted yet for this study

Summary

The value of clinical cardiopulmonary exercise testing (CPET) within healthcare settings has been established in the last decade. CPET methods remain highly relevant in the COVID-19 endemic phase and should be used to assess those recovering from COVID-19 (SARS-CoV-2) infection. This diagnostic tool could play an integral role in disease prognostication and evaluate the integrative response to incremental exercise. Date from such assessments can enable practitioners to characterise cardio-respiratory fitness and identify reasons for physical impairment or abnormal cardio-respiratory function. More than 50% of patients admitted to hospital will experience cardiorespiratory issues and significant morbidity during their recovery and will require significant rehabilitative support. In this context, measurements obtained from an assessment of cardio-respiratory responses to physiological stress could provide insight regarding the integrity of the pulmonary-vascular interface and characterisation of any impairment or abnormal cardio-respiratory function. Current approaches to rehabilitation are being developed on existing knowledge from Severe Acute Respiratory Syndrome (SARS) and Acute Respiratory Distress Syndrome (ARDS) related illness. These provide important insight but do not provide insight into the novel challenges provided by COVID-19.

Conditions

Interventions

PROCEDURE

2 day cardiopulmonary exercise test

Consecutive day 2 day CPET and follow up for 7 days for subjective feelings/fatigue.

Sponsors & Collaborators

  • MS Ramaiah Medical College & Hospitals

    collaborator OTHER

  • University of Illinois at Chicago

    collaborator OTHER

  • University of Nottingham

    collaborator OTHER

  • Northumbria University

    collaborator OTHER

  • King's College London

    collaborator OTHER

  • University of Derby

    collaborator OTHER

  • Sheffield Hallam University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • United States
  • India
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06394921 on ClinicalTrials.gov